These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32005534)

  • 1. GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice.
    Díaz-Trastoy O; Villar-Taibo R; Sifontes-Dubón M; Mozo-Peñalver H; Bernabeu-Morón I; Cabezas-Agrícola JM; Muñoz-Leira V; Peinó-García R; Martís-Sueiro A; García-López JM; Martínez-Olmos MA
    Clin Ther; 2020 Feb; 42(2):e1-e12. PubMed ID: 32005534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
    Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
    Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
    Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
    Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.
    Scoccimarro D; Cipani G; Dicembrini I; Mannucci E
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3727. PubMed ID: 37776322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.
    Sohn M; Nam S; Nauck MA; Lim S
    BMC Med; 2024 Jul; 22(1):273. PubMed ID: 38956548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
    Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
    J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.
    Carretero Gómez J; Arévalo Lorido JC; Gómez Huelgas R; García de Lucas D; Mateos Polo L; Varela Aguilar JM; Seguí Ripoll JM; Ena J;
    Can J Diabetes; 2019 Apr; 43(3):186-192. PubMed ID: 30415909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
    Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
    Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.
    Buckley A; Suliman S; Allum M; Mohammed N; Lessan N; le Roux CW; Suliman M
    Diabetes Obes Metab; 2024 Aug; 26(8):3381-3391. PubMed ID: 38783825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
    Lam CSP; Ramasundarahettige C; Branch KRH; Sattar N; Rosenstock J; Pratley R; Del Prato S; Lopes RD; Niemoeller E; Khurmi NS; Baek S; Gerstein HC
    Circulation; 2022 Feb; 145(8):565-574. PubMed ID: 34775781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.
    Kim HS; Yoon T; Jung CH; Park JY; Lee WJ
    Diabetes Metab J; 2022 Jul; 46(4):658-662. PubMed ID: 34743486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.